These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 19188183)

  • 1. Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.
    Jilaveanu L; Zito C; Lee SJ; Nathanson KL; Camp RL; Rimm DL; Flaherty KT; Kluger HM
    Clin Cancer Res; 2009 Feb; 15(3):1076-85. PubMed ID: 19188183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel.
    Jilaveanu LB; Zhao F; Zito CR; Kirkwood JM; Nathanson KL; D'Andrea K; Wilson M; Rimm DL; Flaherty KT; Lee SJ; Kluger HM
    PLoS One; 2013; 8(8):e69748. PubMed ID: 23936348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib.
    Wilson MA; Zhao F; Letrero R; D'Andrea K; Rimm DL; Kirkwood JM; Kluger HM; Lee SJ; Schuchter LM; Flaherty KT; Nathanson KL
    Clin Cancer Res; 2014 Jun; 20(12):3328-37. PubMed ID: 24714776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.
    Flaherty KT; Schiller J; Schuchter LM; Liu G; Tuveson DA; Redlinger M; Lathia C; Xia C; Petrenciuc O; Hingorani SR; Jacobetz MA; Van Belle PA; Elder D; Brose MS; Weber BL; Albertini MR; O'Dwyer PJ
    Clin Cancer Res; 2008 Aug; 14(15):4836-42. PubMed ID: 18676756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.
    Lee HJ; Wall BA; Wangari-Talbot J; Shin SS; Rosenberg S; Chan JL; Namkoong J; Goydos JS; Chen S
    Clin Cancer Res; 2011 Nov; 17(22):7080-92. PubMed ID: 21844014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512.
    Bhatia S; Moon J; Margolin KA; Weber JS; Lao CD; Othus M; Aparicio AM; Ribas A; Sondak VK
    PLoS One; 2012; 7(11):e48787. PubMed ID: 23226204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
    Augustine CK; Toshimitsu H; Jung SH; Zipfel PA; Yoo JS; Yoshimoto Y; Selim MA; Burchette J; Beasley GM; McMahon N; Padussis J; Pruitt SK; Ali-Osman F; Tyler DS
    Mol Cancer Ther; 2010 Jul; 9(7):2090-101. PubMed ID: 20571072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib in lung cancer: clinical developments and future directions.
    Blumenschein G
    J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S124-7. PubMed ID: 18520294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy.
    Yang J; Zaja-Milatovic S; Thu YM; Lee F; Smykla R; Richmond A
    Mol Cancer Ther; 2009 Mar; 8(3):636-47. PubMed ID: 19276165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma.
    Piguet AC; Saar B; Hlushchuk R; St-Pierre MV; McSheehy PM; Radojevic V; Afthinos M; Terracciano L; Djonov V; Dufour JF
    Mol Cancer Ther; 2011 Jun; 10(6):1007-17. PubMed ID: 21487053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma.
    Flaherty KT; Lee SJ; Zhao F; Schuchter LM; Flaherty L; Kefford R; Atkins MB; Leming P; Kirkwood JM
    J Clin Oncol; 2013 Jan; 31(3):373-9. PubMed ID: 23248256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.
    Davies MA; Fox PS; Papadopoulos NE; Bedikian AY; Hwu WJ; Lazar AJ; Prieto VG; Culotta KS; Madden TL; Xu Q; Huang S; Deng W; Ng CS; Gupta S; Liu W; Dancey JE; Wright JJ; Bassett RL; Hwu P; Kim KB
    Clin Cancer Res; 2012 Feb; 18(4):1120-8. PubMed ID: 22223528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.
    Wilson MA; Zhao F; Khare S; Roszik J; Woodman SE; D'Andrea K; Wubbenhorst B; Rimm DL; Kirkwood JM; Kluger HM; Schuchter LM; Lee SJ; Flaherty KT; Nathanson KL
    Clin Cancer Res; 2016 Jan; 22(2):374-82. PubMed ID: 26307133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results.
    Egberts F; Kahler KC; Livingstone E; Hauschild A
    Onkologie; 2008 Jul; 31(7):398-403. PubMed ID: 18596389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.
    Pölcher M; Eckhardt M; Coch C; Wolfgarten M; Kübler K; Hartmann G; Kuhn W; Rudlowski C
    Cancer Chemother Pharmacol; 2010 May; 66(1):203-7. PubMed ID: 20204367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies.
    Eisen T; Marais R; Affolter A; Lorigan P; Robert C; Corrie P; Ottensmeier C; Chevreau C; Chao D; Nathan PD; Jouary T; Harries M; Negrier S; Montegriffo E; Ahmad T; Gibbens I; James MG; Strauss UP; Prendergast S; Gore ME
    Br J Cancer; 2011 Jul; 105(3):353-9. PubMed ID: 21750549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
    Escudier B; Lassau N; Angevin E; Soria JC; Chami L; Lamuraglia M; Zafarana E; Landreau V; Schwartz B; Brendel E; Armand JP; Robert C
    Clin Cancer Res; 2007 Mar; 13(6):1801-9. PubMed ID: 17363536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
    Azad NS; Posadas EM; Kwitkowski VE; Steinberg SM; Jain L; Annunziata CM; Minasian L; Sarosy G; Kotz HL; Premkumar A; Cao L; McNally D; Chow C; Chen HX; Wright JJ; Figg WD; Kohn EC
    J Clin Oncol; 2008 Aug; 26(22):3709-14. PubMed ID: 18669456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-Raf is associated with disease progression and cell proliferation in a subset of melanomas.
    Jilaveanu LB; Zito CR; Aziz SA; Conrad PJ; Schmitz JC; Sznol M; Camp RL; Rimm DL; Kluger HM
    Clin Cancer Res; 2009 Sep; 15(18):5704-13. PubMed ID: 19737955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).
    Margolin KA; Moon J; Flaherty LE; Lao CD; Akerley WL; Othus M; Sosman JA; Kirkwood JM; Sondak VK
    Clin Cancer Res; 2012 Feb; 18(4):1129-37. PubMed ID: 22228638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.